Neutral Backbone Modifications Enhance the Pharmacokinetics and Biodistribution of Antibody–Oligonucleotide Conjugates with High Drug-to-Antibody Ratios
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c00565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Michael Cochran und 13 weiteren Autor:innen. Beteiligte Einrichtung: Avidity Biosciences , A Novartis Company. 3020 Callan Road, San Diego, California92121, United States. Hauptthemen laut MEDLINE: Immunoconjugates, Oligonucleotides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Avidity Biosciences, A Novartis Company.
Abstract (Originalsprache)
Antibody–oligonucleotide conjugates (AOCs) enable targeted delivery of small interfering RNAs (siRNAs) by coupling them to antibodies for receptor-mediated uptake, enhancing tissue specificity and therapeutic potential. A key determinant of AOC performance is the drug-to-antibody ratio (DAR), which influences pharmacokinetics, biodistribution, and knockdown efficiency. Prior studies with transferrin receptor 1 (TfR1)-targeted AOCs revealed that DAR ≥2 constructs exhibit rapid plasma clearance, preferential hepatic uptake, and reduced muscle delivery compared with DAR1. We hypothesized that increased negative charge from multiple phosphodiester and phosphorothioate linkages drives nonspecific plasma protein binding and scavenger receptor-mediated clearance of DAR2 AOCs. To test this, we investigated siRNA modifications designed to reduce charge and phosphorothioate content, including phosphorothioate removal and incorporation of neutral backbone chemistries such as phosphoryl guanidine (PG), methoxypropylphosphonate, and triester linkages. PG-modified DAR2 AOCs improved pharmacokinetics and tissue distribution in mice while maintaining activity. These findings lay the groundwork for optimizing high-DAR AOCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Avidity Biosciences , A Novartis Company. 3020 Callan Road, San Diego, California92121, United States.
- Former Employee of Avidity Biosciences, A Novartis Company, San Francisco, California92121, United States.
- Seawolf Therapeutics, 1 Sansome Street Suite 3630, San Francisco, California94104, United States.
ORCID-Profile: Venkata Ramana Doppalapudi
Förderung
- Avidity Biosciences, A Novartis Company
Zitieren
APA
Cochran, M., Nallagatla, S., Iacono, G. D., Abdulkadir, S., Arias, D., Jordan, M., Kwon, H. W., Levin, A., Hood, M., Kovach, P., Kim, A., Burke, R., Malecova, B., & Doppalapudi, V. R. (2026). Neutral Backbone Modifications Enhance the Pharmacokinetics and Biodistribution of Antibody–Oligonucleotide Conjugates with High Drug-to-Antibody Ratios. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00565
Vancouver
Cochran M, Nallagatla S, Iacono GD, Abdulkadir S, Arias D, Jordan M, et al. Neutral Backbone Modifications Enhance the Pharmacokinetics and Biodistribution of Antibody–Oligonucleotide Conjugates with High Drug-to-Antibody Ratios. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00565
BibTeX
@article{Cochran2026,
author = {Cochran, Michael and Nallagatla, Subbarao and Iacono, Giuseppe Dello and Abdulkadir, Sami and Arias, Danny and Jordan, Maryam and Kwon, Hae Won and Levin, Arthur and Hood, Michael and Kovach, Philip and Kim, Aidan and Burke, Rob and Malecova, Barbora and Doppalapudi, Venkata Ramana},
title = {Neutral Backbone Modifications Enhance the Pharmacokinetics and Biodistribution of Antibody–Oligonucleotide Conjugates with High Drug-to-Antibody Ratios},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c00565}
}
EUVIMED